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Summary
The physical association of 40 antigenic peptides and purified HLA class I and class II molecules
was monitored using a direct peptide binding assay (PBA) in solid phase and an inhibition peptide
binding assay (IPBA) in which the competing peptide was present in a soluble phase. We also
examined the ability of different peptides to inhibit the lytic activity of human antiviral cytolytic
T cells towards cells incubated with the corresponding target peptide. Our results showed that:
(a) Binding ofa given human T cell-recognized peptide to several HLA classI and class II molecules
occurred frequently. Nevertheless, preferential binding of peptides to their respective restriction
molecules was also observed. (b) Binding of HLA molecules to peptides recognized by murine
T cells occurred less frequently. (c) 11 of 24 (46%) randomly selected HIV-1 peptides contained
agretopic residues allowing their binding to HLA molecules. (d) The kinetics of HLA/peptide
association depended on the peptide tested and were faster than or similar to those reported for
Ia molecules. Dissociation of these complexes was very low. (e) Peptide/HLA molecule binding
was dependent on length, number of positive charges, and presence of hydrophobic residue in
the peptide. C A correlation was demonstrated between a peptide inhibitory effect in the IPBA
and its blocking effect in the cytolytic test. Our data indicated that the restriction phenomenon
observed in T cell responses was not strictly related to either an elective HLA/peptide association,
or a high binding capacity of a peptide to HLA molecules. These data also showed that the
PBA and IPBA are appropriate for the detection of agretopic residues within HIV-1 proteins.
T
cells recognize antigens as small peptides bound to class
I or class II MHC molecules (1-3). In most cases, T cell
epitopes are recognizedin association with only a few, ifnot
a single, MHC restriction elements (reviewed in reference
4). In contrast, some peptides can be recognized in associa-
tion with several la (5) or HLA-DR molecules (6, 7). Fur-
thermore, a single peptide can be recognized by both MHC
class I- and class II-restricted T cells (8, 9). Since class I and
class II molecules have a similar predicted tertiary structure,
including a single antigen binding site (10-12), interactions
between peptides and these two types of molecules are also
likely to be similar. The binding site is represented as a plat-
form ofeight antiparallel /3-strandstopped by ot-helices. The
(3-pleated sheets contain a large number of conserved hydro-
phobic residues, whereas the ci-helices contain more poly-
morphic residues (10, 11). Garrett et al. (13) have recently
described several pockets apparently positioned to bind pep-
tide side chains. The variable shapes and charges of these
pockets might explain their different reactivities with mul-
tiple peptides. However, the molecular mechanism of pep-
tide/MHC molecule association remains unclear: the con-
formations, orientations, and numbers of peptides interacting
with a binding site are still hypothetical.
The formation of complexes between antigenic peptides
and MHC class II molecules has been directly demonstrated
in binding experiments involving labeled peptides and purified
murine class II molecules either in soluble phase (14, 15),
or in planar membranes (16). Although a physical associa-
tion between HLA class I molecules and immunogenic pep-
tideshas been recently reported (17, 18), very little is known
on peptide binding of class I molecules. We have previously
described an assay to measure both the binding of radiola-
beled HLA class I molecules to peptides attached to a sup-
port and the inhibition of this binding by soluble peptides
(18). By using this assay, we showed that class I molecules
bound to peptides described to be targets ofclass I-restricted
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to bind different HLA class I molecules, this indicated that
interaction with MHC molecules was necessary but not
sufficient for T cell recognition. In this paper, using both
the direct peptide binding assay (PBA)' and the inhibition
of peptide binding assay (IPBA), we analyzed the physical
interactions between HLA molecules and 40 synthetic pep-
tides. The peptides studied included specific targets for ei-
ther CD4+ or CD8' T cells, as well as a large number of
peptides derived from HIV proteins and not yet described
to bear T cell-reacting epitopes.
Materials and Methods
PurifiedHLA Preparations.
￿
Purified HLApreparations were ob-
tained from threehuman lymphoblastoid cell linestransformed by
EBV:JES THOM (HLA-A2/2,1327/27, DR1/1), HHKB (HLA-
A3/3, B7/7, DRW 13/13), and KAS-011 (HLA-Al/1, 1337/37,
DR 2/2) . Cells were lysed in 10 mM Tris-buffered saline (TBS),
pH 7.5, containing 1% NP-40 (Sigma Chemical Co., St. Louis,
MO) in the presence of protease inhibitors: 1 mM p-amidino-
phenyl-methyl-sulfonyl-fluoride, 10 pg/ml trypsin inhibitor, 10-5
M pepstatin A, 10-5 M leupeptin, and 10 -^ M iodoacetamide
1 Abbreviations used in this paper: IPBA, inhibition of peptide binding
assay; PBA, peptide binding assay.
890 Interactions between Peptides and Purified HLA
(Sigma Chemical Co.). After centrifugation, supernatants were run
through different columns as describedby Walker andReisfeld (19).
Briefly, the columns, equilibrated in TBS containing 0.1% NP-40
andprotease inhibitors, consistedofthesuccession of: (a) a CNBr-
activated-Sepharose 413column (Pharmacia France, SaintQuentin
Yvelines), (b) a CNBr-Sepharose 413 column coupled to normal
BALB/c immunoglobulins, and (c) aCNBr-Sepharose 413column
coupledto anti-HLA mAbs. Purified immunoglobulins BB7.2 (20)
and B27M2 (21) were used for HLAA2 and -1327, respectively.
Enriched HLAB27 or -1337 preparations were also obtainedby using
131.23.2, which reacts with most HLA-B molecules (22). HLA-
DR preparations were obtained by using L243 (23). After three
successive washes with TBScontaining 1% NP-40, then TBS with
0.5 M NaCl and 0.1% NP-40, and finally PBS containing 0.1%
N-octylglucopyrannoside (Sigma Chemical), HLA molecules were
eluted from thecolumnswith 0.05 M diethylamine, pH 11.5. Eluted
fractions were immediately neutralized with 1 M Tris-HCI, pH
8.0. After an overnight dialysis at 4°C in PBS containing 0.1%
NP-40, samples were aliquoted and frozen at -80°C. Purity of
fractions was assessed by SDS-PAGE and IEF-PAGE after iodina-
tion of the HLA samples. Protein concentration was determined
by using the BCA reagent (Pierce Chemical Co., Rockford, IL).
Iodination of HLAmoleculeswasperformedby using the chlora-
mine T method with 10 Fcg of purified HLA and 18.5 MBq
"'iodine.
SyntheticPeptides.
￿
Peptidesprepared by solid-phase synthesis were
obtained from Neosystem (Strasbourg, France). Sequences are given
Table 1. Synthetic Peptides Tested for Binding to HLA Molecules
Peptide Sequence Restricting element Reference
Influenza A virus
Matrix
M.57-68 K G I L G F V F T L T V HLA-A2 (24)
M.Y457-68 Y K G I L G F V F T L T V HLA-A2 (18)
Nucleoprotein
N.147-158R- TYQRTRALVTG H-2 Kd (25)
N.335-349Y' S A A F E D L R V L S F I R G Y HLA-1337 (3)
Haemagglutinin
H.130-142 H N T N G V T A A C S H E lad (26)
H.305-329 C P K Y V K Q N T L K L A T G M R N V P E K Q T R HLA-DR (1)
Lysosyme: Lys.46-61 N T D G S T D Y G I L Q I N S R lak (14)
A repressor: XR.12-26 L E D A R R L K A I Y E KKK lad (27)
HLA-A2: A2.170-185 R Y L E N G K E T L Q R T D A P H-2 Kd (28, 29)
HIV 1
Gag. 51-65 L E T S E G C R Q I L G Q L Q
205-219 ETINEEAAEWDRVHP
219-233 HAGPIAPGQMREPRG
265-279 K RW I I L G L N K I V R M Y HLA-1327 (30)
378-391 MQRGNFRNQRKIVK
418-433 KEGHQMKDCTERQANF HLA-A2 (31)
continuedin Table 1.They were derivedfrom influenzaAvirusproteins (Ma-
trix, nucleoprotein, or hemagglutinin), hen egg lysozyme, X
repressor, HLAA2 molecule, and HIV-1 proteins (Gag, Env, Nef,
Vif, Rev, andVpr) oftheBRUisolate(36). Peptides Gag. 205-219
andGag. 265-279 were derived from the HIV-1 SF2 isolate (30).
Direct Peptide Binding Assay.
￿
Wells of microtiter plates were
pretreated with 100 ul 2.5% glutaraldehyde in distilled water for
2 h at 20°C, washed with distilled water, and coated for 16 h at
4°Cwith 100Al of peptide diluted at 5 itg/ml either in carbonate-
bicarbonate buffer, pH 9.6,or in PBS, pH 7.4 or pH 5.0. Remaining
free sites were blocked by incubation for 2 h at 20°C with BSA
diluted 1% in PBS containing 0.05% Tween 20 (Tw) and 0.02%
sodium azoture. After washing, purified 1151-HLA molecules (100
,ulcontaining 1.5 x 101 cpm, 10-9 M) diluted in PBS containing
1% BSA, 0.05% Tw, 0.02% sodium azoture, 1 mM PMSF, and
10 Ftg/ml trypsin inhibitor were added and incubated for 20 h at
20°C. After extensivewashing, the radioactivity of each well was
counted. Each peptide was tested in triplicate and the average of
three independent experiments was calculated.
Inhibition IkptideBindingAssay.
￿
Concentrations of0.1-100 uM
of competitor peptides were incubated in tubes for 0-3 h at 20°C
with "'I-HLA (10-' M) diluted in PBS-BSATw containing the
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protease inhibitors as mentioned above. Then themixturewas added
to microtiter plate wells coated with a peptide that showed
significant binding to HLA molecules in the direct test and in-
cubated 20 h at 20°C. After extensive washing, the radioactivity
in each well was counted and the percent of inhibition was calcu-
lated. Each peptide was tested in triplicate and in three indepen-
dent experiments.
Competition between Peptides in a LyticAssay.
￿
Human antipep-
tide CTLwere generatedas describedby Carboneet al. (37). Briefly,
6-8 x 10' PBMC were stimulated with 100 kg of a synthetic
peptide in 10 ml culture medium (RPMI 1640 supplemented with
100 Et/ml penicillin, 100FAg/ml streptomycin, 2 MM L-glutamin,
2 mM nonessential amino acids, 1 mM sodium pyruvate, 10 mM
Hepes, and 10% pooled heat-inactivated human AB serum). After
a 7-d incubation, a secondary in vitro stimulation was performed
by mixing 5-7 x 106 effector cells with 2-3 x 10' irradiated
(4,000 rad) autologous PBMC in 10 ml culture medium containing
50-100 ug of peptide.
Weekly restimulations were similarly performed in culture
medium supplemented with 5% ofID2-containing supernatant pre-
pared as describedby Healy et al. (38). CTLfrom an HLAA2/3,
B7/60, DR4/8 donor recognizing the peptides M.57-68 and
" Non precisely identified restricting element.
t Culmann B., E. Gomaud, M.-P. Kieny, B. Guy, F. Dreyfus, A.-G. Saimot, D. Sereni, D. Sicard andJ.-P. Levy, manuscript submitted for
publication.
Table 1. (continued)
Peptide Sequence Restricting element Reference
Env. 105-117 H E D I I S L W D Q S L K la* (32)
312-327 I RIQRGPGRAFVT I GK H-2 Dd (33)
428-445 F I N MW Q E V G K A M Y A P P I S la* (32)
474-489 R P G G G D M R D N W R S E L Y
510-521 VVQREKRAVG I G
584-604 R I L A V E R Y L K D Q Q L L G I W G C S HLA, Cl II' (34)
827-843 YVAEGTDRV I EVVQ GACR -
846-860 R H I P R R I R Q G L E R I L -
Nef. 66-80 VGF PVT PQV P LRPM T -
79-94 MTYKAAVDL S H F L K E K -
113-128 WI YHTQGY F PDWQN Y T HLA-B17.37 (35)
132-147 GVRY P L T F GWCYKL V P HLA-B18 Our lab#
137-145 L T F G WC Y K L
160-174 ENTSLLHPVSLHGM D
Vif. 1-15 MENRWQVM I VWQVD R
25-40 VKHHMYVSGKARGW F Y
46-60 S P H P R I S S E V H I P L G
60-72 GDARL V I TTYWGL
71-85 GLHTGERDWHLGQG V
Rev. 1-16 MAGRS GDSDEDLLK AV
18-30 L I KF LYQSNP P PN
37-50 ARRNRRRRWRERQR
Vpr.1-14 MEQAPEDQGPQREP
55-68 AGVEAI IRI LQQLL
68-80 LF IHFRI GCRHSRM.Y'57-68 in association with the HLA-A2 molecule and CTL
from an HLAA2/11, B5/37, DR2/3 donor recognizing the pep-
tide N.335-349Y' in association with the HLA-B37 molecule
were used in the lytic assay. The target cells were "Cr-labeled au-
tologous EBVtransformed B lymphoblastoid cell lines. Blocking
assays were performed by preincubating "Cr-labeled target cells
for 1 h at 37'C with competitor peptides at concentrations ranging
from 100 to 10 A.M. The target peptide was then added at a final
concentration of 0.4 /AM (MY' 57-68) or 2 I.M (N.335-349Y')
with the effectors at an E/T ratio of 4:1. Chromium release into
the supernatant was measured in a gamma counter. Specific lysis
was calculated as: 100 x[(experimental-spontaneous release)/(total
"Cr incorporated-spontaneous release)]. Maximal specific lysis was
obtained in the absence ofcompetitor peptide. Theresultsofdupli-
cateswere expressedas: percent inhibition ofmaximal specific lysis
= [1 - (experimental specific lysis/maximalspecific lysis)] x 100.
Results
Binding ofHLA Class IMolecules to Peptides Recognized by
Either CD8' or CD4' T Cells. Using the PBA, we tested
nine peptides described to be targets for class I-restricted CTL.
Three peptides corresponded to theinfluenza Avirus matrix
(M.57-68 and MY' 57-68) and nucleoprotein (N.335-
349Y') protein; their recognition by human CTL was re-
stricted by HLAA2 (24) andHLAB37 (3), respectively. Three
other peptides were derived from HIV-1 Gag (Gag.265-279
and Gag.418-433), and Nef (Ne£113-128) proteins; the re-
striction molecules for these peptides were HLA-B27 (30),
HLA-A2 (31) and HLA-B17 + B37 (35), respectively. The
last 3 peptides were H-2a-restricted targets of murine CTL
issued from the nucleoprotein of theInfluenzaAvirus(N.147-
158R -) (25), the HIV-1 Env protein (Env.312-327) (33), the
HLA-A2 molecule (A2.170-185) (28, 29), respectively.
As illustrated in Table 2, in all cases, a significant reac-
tivity of each peptide with its restriction molecule was ob-
served. Also, and accordingto ourprevious report (18), HLA
A2 bound more efficiently peptide MY+ 57-68 than the nat-
ural peptide M57-68. We verified that all thematerial retained
Table 2.
￿
Direct Binding of HLA Class 1 Molecules to
Peptides Described as Target for MHC Class I-restricted CTL
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Table 3.
￿
Direct Binding of HLA Class I Molecules to
Peptides Bearing MHC Class II-associated Epitopes
Wells of microtiter plates were coated with 5 jug/ml of peptide and
1.5 x 105 cpm of iodinated HLA molecules were added. Each value
represents the average of three independent experiments.
' Nonprecisely identified restricting element. The results corre-
sponding to the restricting HLA molecule are underlined in Table 2.
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Time course of peptide/HLA association. Synthetic pep-
tides (10 fig/ml) were immobilized onto microtiter plate wells as in-
dicated in Materials and Methods. The buffers used were respectively:
PBS, pH 7.4, for peptides MY'57-68 (") and M.57-68 (O), PBS,
pH 5.0, for peptides N.335-349Y' (*). N.147-158R- (A), and
Gag.418-433 (0) and carbonate-bicarbonate buffer, pH 9.6, for pep-
tides Gag.265-279 (A) and Env.312-327 (0). Binding of iodinated
HLA-A2 (a) -B27 (b) molecules (2 x 105 cpm) was determined by
radioactivity counting.
Peptide
Restricting
element
HLA
A2
bound
B27
(cpm)
B37
M.57-68 HLA-A2 926 677 924
M.Y'57-68 HLA-A2 9,150 2,073 2,908
N.335-349Y' HLA-B37 5,200 658 2,175
Gag.265-279 HLA-B27 24,010 37,590 23,000
Gag.418-433 HLA-A2 633 0 294
Nef.113-128 HLA-B17,-B37 0 0 701
N.147-158R- H-2 Kd 0 0 0
Env.312-327 H-2 Dd 22,800 23,241 21,066
A2.170-185 H-2 Kd 0 0 0
Peptide
Restricting
element
HLA
A2
bound
B27
(cpm)
B37
Env.584-604 HLA.II' 1,200 1,081 2,206
H.305-329 HLA.DR" 15,898 3,915 3,050
H.130-142 lad 0 0 0
XR.12-26 lad 6,807 354 943
Env.105-117 la" 0 0 0
Env.428-445 Ia" 2,600 0 0
Lys.46-61 lak 2,709 0 516Table 4.
￿
Concentration of Soluble Peptide Required for 50% Inhibition of HLA/Peptide Association
Results are expressed as p.M of competitor peptide giving 50% inhibition of binding. Wells were coated with 5 'cg/ml M.Y+57-68, in PBS,
pH 7.4, 5 ug/ml Gag.265-279 in buffer pH 9.6, and 10 pg/ml N.335-349Y+ in PBS pH 5. Maximum response obtained for HLA-A2/
M.Y+57-68 was 8,000-12,000 cpm., for HLA-B27/Gag.265-279, 30,000-40,000 cpm, and for HLA-B37/N .335-349Y+, 6,000-8,000 cpm. N,
No competitor effect; E, enhancement of binding.
Nonprecisely identified restriction molecule.
on peptides had the migration pattern of HLA class I mole-
cules by using IEF electrophoresis (not shown). Peptides such
as M.57-68, MY+57-68, N.335-349Y+, or Gag.265-279
had a high binding efficiency and in addition to their restric-
tion molecule bound also other class I molecules. In con-
trast, less efficient peptides interacted only or preferentially
with their restriction molecule. Interestingly, peptide N.335-
349Y+, which was HLAB37-restricted, interacted more
efficiently with HLA-A2 than with HLA-B37 molecules, but
still reacted very weakly with HLA-1327 molecules. Among
the three peptides described as targets for murine CTL and
restricted by H-2Kd or H-2Dd, only Env.312-327 bound
very efficiently the three HLA class I molecules tested.
Table 3 shows typical results obtained with seven peptides
described as targets for MHC class II-restricted T cells. Pep-
tides H.305-329 and Env.584-604 corresponded to the hemag-
glutinin of influenza virus and the HIV-1 Env protein, respec-
tively. These two peptides containing epitopes recognized by
human CD4+ T cells bound efficiently the three HLA class
I molecules tested. The five other peptides were recognized
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by murine T cells in the context of an Ia molecule (see Table
1) and three of them associated with HLA molecules.
Altogether, these experiments showed, on the one hand,
that the ability for a given peptide to bind several HLA mol-
ecules is a frequent event, and, on the other hand, that the
peptides known as targets for murine T cells reacted less
efficiently with HLA molecules than peptides bearing human
T cell-reactive epitopes.
Time Course ofAntigenic Peptide/HLA Complex Forma-
tion. To study the kinetics of formation of peptide/HLA
complex in solid phase, iodinated HLA-A2 and -1327 mole-
cules were tested for their ability to interact with immobi-
lized peptides between 30 min and 48 h ofincubation at 20°C.
Fig. 1 shows that most of the binding occurred at 6 h, al-
though a plateau was not reached before 24 h in most cases.
The equilibrium level varied considerably depending on the
peptide, and to a lesser extent, on the HLA class I molecule
(Fig. 1). In these solid phase conditions, the dissociation rate
of peptide/HLA complexes was very low for all the mole-
cules tested. This rate did not exceed 20% after 24 h of incu-
Competitor
peptide
Restricting
element
HLA-A2
+
M.Y+57-68
HLA/Peptide association
HLA-1327
+
Gag.265-279
HLA-B37
+
N.335-349Y+
'um #M 'UM
M.57-68 HLA-A2 10 30 10
M.Y+57-68 HLA-A2 0.1 3 5
N.335-349Y+ HLA-B37 0.3 3 10
Gag.265-279 HLA-1327 30 10 E
Gag.418-433 HLA-A2 30 >100 E
Nef.113-128 HLA-1317-37 30 30 >100
N.147-158R- H-2 Kd N N N
Env.312-327 H-2 Dd >100 N N
A2.170-185 H-2 Kd N N N
Env.584-604 HLA-Cl lI' 30 30 100
H.305-329 HLA-Cl DR" >100 N N
H.130-142 Iad N N N
XR.12-26 lad N N N
Lys.46-61 lak 100 100 100
Env.105-117 Ia" 3 100 10
Env.428-445 Ia" 10 30 100bation either in the presence of the relevant solubilized pep-
tide or without addition of peptide (not shown) .
Inhibition by Antigenic Peptides ofDifferentPeptide/HLA Class
I Molecule Associations.
￿
Since the PBA might be influenced
by altered peptide conformation after immobilization on
glutaraldehyde-treated microtiter plate wells, false-negative
results might be due to this alteration. For this reason, quan-
titative IPBA was performed systematically to compare the
ability of peptides to inhibit three different HLA/peptide as-
sociations. We tested the HLA/peptide associations of HLA-
A2/MY+57-68, HLA-B27/Gag.265-269, and HLAB37/
N.335-349 Y+ .
All peptides described as targets for HLA class I-restricted
CTL had an efficient competitive activity in at least two of
the three HLA/peptide systems tested. The HLAA2-restricted
peptides M.57-68 and M.Y+57-68 and the HLA-B37-
restricted peptide N.335-349Y+ were particularly efficient
competitors in all three systems (Table 4). Some peptides had
variable competitive activities: also, we observed that the HLA
1327-restrictedpeptide Gag.265-279 and the HLAA2-restricted
peptide Gag.418-433 did not inhibit the HLAB37/N.335-
349 Y+ association, but gave strong enhancements of binding
at concentrations varying from 0.3 to 10 p.M. Interestingly,
the HLA-1317 and B37-restricted peptide, Nef.113-128, com-
peted more efficiently in systems involving HLA-A2 or B27
molecules than in the HLAB37/N.335-349Y+ system. The
Table 5.
￿
Interaction ofHLA-Class II Molecules with Peptides Described as Targets for CD4+ or CD8+ T Cells
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three murine class I-restricted peptides did not inhibit the
HLA/peptide interactions with the exception of a weak in-
hibition (ti30%) obtained with 100 LtM of Env.312-327 on
the HLA-A2/MY+57-68 association. Finally, among the
seven class II-restricted peptides tested, two did not com-
pete, two competed weakly, and three peptides derived from
the HIV-1 Env protein sequence competed in the three HLA/
peptide associations with different efficiencies.
Association ofAntigenic Peptides with HLA Class II Mole-
cules. Since peptides described as targets for class II-restricted
CD4+ T cells bound HLA class I molecules, we examined
whether peptides described to be classI-restricted CTL targets
could also bind HLA class II molecules. 14 antigenic pep-
tides were tested in the PBA, and in the IPBA usingthe HLA
DRw13/H.305-329 association as reference system (Table 5).
Peptides that had a high ability to bind HLA class I mole-
cules in the previous experiments (H.305-329, Env.312-327,
MY+57-68, or Gag.265-279) also bound efficiently class II
molecules (Table 4) . Peptides that had a low interaction with
class I molecules (Env.428-445 or XR.12-26) also had low
interaction with class II molecules. The two peptides shown
to be HLADRrestricted, H.305-329 and Env.584-604, bound
the two HLADR molecules tested in the PBA, whereas la-
restrictedpeptides either were negative or reacted only with
HLADR2 . Using the IPBA, we found that the antigenic
peptides acting as efficient competitors on HLA class I/pep-
PBA
Interactions between Peptides and Purified HLA
IPBA
IPBA, Results are expressed as concentration (ttM) of peptide giving 50% inhibition of binding on the HLA-DRw13/H.305-329 association.
The maximum response was 4,500 cpm.
N, No competitor effect.
Peptide
Restricting
element
HLA
DR2
bound (cpm)
DRW13 HLA-DRw13/H.305-329
'UM
H .305-329 HLA-DR 3,900 3,147 50
Env.584-604 HLA-Cl II 600 1,308 10
Env.105-117 Ia 0 0 50
Env.428-445 la 806 0 >100
Lys.46-61 Iak 0 0 30
XR.12-26 Iad 1,200 0 N
H.130-142 lad 0 0 N
Env.312-327 H-2 Dd 4,806 11,911 N
A2 .170-185 H-2 Kd 0 0 N
M.Y + 57-68 HLA-A2 4,162 4,943 0.1
N.335-349 Y+ HLA-1337 390 897 1
Gag.265-279 HLA-1327 12,300 22,580 10
Gag.418-433 HLA-A2 0 0 100
Nef.113-128 HLA-1317 + B37 0 0 3tide associations were also efficient competitors on the HLA-
DRw13/H.305-329 association.
Systematic Attempts to Detect HLA Class I Binding to HIV
Peptides. All the peptides used above have been shown pre-
viously to serve as targets in either class I- or class II-re-
stricted T cell responses. We also tested a more important
panel of HIV peptides regardless of their ability to serve as
T cell targets. 24 HIV peptides not yet described to be T
Table 6.
￿
Binding of HLA Class I or Class 77 Molecules to HIV Peptides not Described as T Cell Targets
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cell antigens were randomly chosen. Using the PBA, 14 of
these peptides (58%) did not bind the HLA molecules tested
(Table 6) . Peptide Vpr.55-68 reacted weakly with both HLA-
B37 and DRw13. The nine remaining peptides reacted with
all three HLA molecules tested. Using the IPBA, six pep-
tides had competitor activity in the three HLA/peptide
associations tested: Ne£137-145, Vi£1-15, Vif.60-72, Rev.18-
30, Vpr.55-68, and Vpr.68-80. Peptides Vif.25-40 and Nef.132-
The IPBA results are expressed as concentration (AM) of peptide giving 50% inhibition of HLA/reference peptide binding. Maximum response
for HLA-A2/M.Y+57-68 was 8,000-12,000 cpm, for HLA-B37/N.335-349Y+, 6,000-8,000 cpm and for HLA-DRwl3/H.305-329,
4,000-5,000 cpm. N, No competitor effect; E, enhancement of binding.
* Peptide 132-147 gave a maximal inhibition of 30% at 10 and 100 A.M.
HIV
Peptide A2
PBA
HLA bound
B37 DRw13
HLA-A2
M.Y+ 57-68
IPBA
HLA-B37
N.335-349Y +
HLA-DRw13
H.305-329
cpm ,UM PM UM
Nef
66-80 0 0 0 N N N
79-94 0 0 0 N N N
132-147 18,504 31,882 29,883 E 10
137-145 6,638 5,718 2,515 10 3 0.1
160-174 0 0 0 N N N
Vif
1-15 3,100 3,714 3,468 3 10 0.1
25-40 9,368 31,500 27,595 30 E 1
46-60 0 0 0 N N N
60-72 350 3,588 2,326 30 100 30
71-85 0 0 0 N N N
Rev
1-16 0 0 0 N N N
18-30 0 0 0 100 100 10
37-50 6,150 10,262 13,729 >100 E >100
Vpr
1-14 0 0 0 N N N
55-68 0 722 437 3 10 100
68-80 40,768 34,031 24,356 1 10 0.1
Gag
50-65 0 0 0 N N N
205-219 0 0 0 N N N
219-233 0 0 0 N N N
378-391 30,874 15,596 34,278 N N N
Env
474-489 0 0 0 N N N
510-521 0 0 0 N N N
827-843 0 0 0 N N N
846-860 5,400 2,402 944 >100 N N147 had either competitor or enhancer activity depending
on the system tested. Peptide Rev.37-50, which had a high
binding in the PBA, had either a very low competitor ac-
tivity or an enhancing effect in the IPBA. Also, peptide
Env.846-860, competed poorly in one association only. The
other 14 peptides (58%) did not compete at all.
Using Table 7, one can figure the different possible pat-
terns ofreactivity obtained in the PBA and in the IPBA with
this panel of HIV peptides in comparison with previously
described antigenic peptides. All the peptides bearing human
T cell epitopes interacted with HLA molecules, whereas 62%
ofthe peptides bearing murine T cell epitopes and only 46%
of randomly selected HIV-1 peptides did.
Correlation between the Competitor Activity of Peptides in IPBA
and their Ability to Inhibit CTI mediated Cytolysis. The results
obtained in the IPBA strongly suggest that different peptides
compete for the same binding site on HLA molecules. To
determine the functional significance of these data, nine non-
HIV antigenic peptides and eight HIV peptides not described
as antigens were tested for their ability to inhibit the cyto-
lyticinteraction between anti-influenza A CTL and cells in-
cubated with the relevant target peptide. As shown in Table
8, in 15 of these 17 peptides a good correlation was observed
between the competitor activity detected in the IPBA and
the blocking effect observed in the cytolytic test. Discrepan-
cies were observed in only two cases: (a) Peptide Lys.46-61
partially inhibited the binding in the IPBA but did not block
the CTL induced lysis; (b) peptide Gag.265-279 gave puz-
zling results: it enhanced the lysis by relevant CTL of HLA-
B37+ cells incubated with N.335-349Y+, and in agreement
with these data, this peptide provided enhancement in the
IPBA. However, when tested on the HLAA2/MY+57-68
association, the same peptide enhanced the lysis, although
it had either a low competitor activity or an enhancing effect
in the IPBA.
Discussion
In the present study we identified general characteristics
of the physical interactions between antigenic peptides and
HLA class I molecules. Using a recently described method
(18), we found that the kinetics of binding of HLA mole-
cules varied with the peptide studied and were similar to or
Table 7.
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faster than those observed with murine class II molecules by
using equilibrium dialysis (39). In addition, the resulting HLA
class I/peptide complexes were extremely stable. We also found
that the binding efficiency of HLA molecules was variable:
<1% for most peptides, but reaching 6% in some cases, and
even 15-25% in the cases ofpeptides Gag.265-279, Env.312-
327, or Vpr.68-80. These numbers were unusually high when
compared with bindings obtained with HLA class I mole-
cules by using other methods (17). Nevertheless, our results
were in agreement with the recently reported data ofDemotz
et al. (40) demonstrating that 10-40% of I-Ed molecules
couldbe occupied by naturally processed peptides ofhen egg
lysozyme. Since, during our experimental conditions, purified
HLA molecules were most likely occupied by endogenously
bound peptides, as reported for murine class II molecules (41),
such high levels of specific binding were surprising. This could
be due either to the fact that 25% of HLA class I molecules
might be naturally free of peptides, and/or to the fact that
a proportion of endogenous peptides could be readily sub-
stituted. Another possibility would be that exogenous pep-
tides bind HLA molecules already occupied by endogenous
peptides, although this would be in opposition to the crys-
tallography data of HLA-A2 molecule (10, 11) according to
which there is only a single peptide binding site per molecule.
Our data obtained with peptides derived from the same
region of a given protein and varying in length, indicated
the importance of the size of the peptide in binding. Thus
peptide Ne£132-147 bound very efficiently in the PRA, al-
though this peptide poorly inhibited the HLAA2/MY+57-
68 association, or-did not at all inhibit the HLAB37/N .335-
349 Y+ association. In contrast, the shorter analogue of this
peptide, Nef.137-145, had a low level of binding in the PBA
and a strong inhibitory activity in the IPBA. The immobili-
zation of this latter nine residue long peptide onto microplates
might have modified its structure and reactivity. Neverthe-
less, the inability ofthe larger peptide to compete in the IPBA
remains to be elucidated.
The different patterns of HLA/peptide interaction observed
in the PBA and IPBA showed that 9 of 24 (38%) HIV-1 pep-
tides not yet described as antigens reacted in both assays,
whereas 1 of 24 (4%) bound only in the PBA, and the same
proportion reacted only in the IPBA . When testing a panel
of 156 HIV-1 peptides, including a minority of previously
Pattern
Peptide
1
PBA +
IPBA +
2
PBA +
IPBA -
3
PBA -
IPBA +
4
PBA -
IPBA -
Reactive peptides
(number tested)
Human CD4+ or CD8+ epitopes 8 0 0 0 8/8 (100%)
Murine CD4+ or CD8+ epitopes 2 2 1 3 5/8 (62%)
Randomly chosen HIV peptides 9 1 1 13 11/24 (46%)described T cell epitopes, the numbers observed were 44 of
156 (28%), 17 of 156 (11%), and 12 of 156 (8%), respec-
tively (Choppin, J., F. Nartinon, F. Connan, N . Pauchard,
E. Gomard andJ. P. Levy, manuscript submitted for publica-
tion). The differences observed between the numbers obtained
with the two assays can be due to: (a) conformational altera-
tionsofpeptides immobilized onto the microplate wells which
might result in false-negative results in the PBA; (b) to fixa-
tion ofthe peptide on the HLA molecule at a position which
is different of that of the reference peptide used in the IPBA
and might result in non-inhibitory effect. This simultaneous
fixation of two peptides might increase the capacity of inter-
action of the HLA molecules with the reference peptide by
conformational effect and explain the enhancing effect ob-
served with certain peptides as reported also by Bhayani and
Paterson (42) in functional assays; (c) to a peptide/peptide
interaction which might also allow the fixation of two pep-
tideson a single HLA molecule and give false-negative results
in the IPBA. We are currently investigating these possibilities.
In our experiments, a high binding in the PBA (>6%)
correlated to the presence ofpositive charges. Thus, peptides
giving the highest bindings, such Gag.265-279, Env.312-327,
Nef.132-147, Vif.25-40, Rev.37-50, Vpr.68-80, or Gag.378-391,
have three to eight positive charges in their sequences. In con-
trast, a competitor activity in the IPBA did not correlate to
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the presence of positive charges, but rather was dependent
on the presence of several hydrophobic residues. Bogen and
Lambris (43) have indicated the importanceofpositive charges
for the binding of peptides to I-Ed molecules and suggested
the implication of such charged residues in salt bridges es-
tablished with the negative charges of MHC molecules. Ini-
tial formation of such salt bridges would then be followed
by formation of a stable binding between the hydrophobic
residues of a peptide and the underlying 0 strands. In pep-
tides comprising numerous positive charges, the initial in-
teraction would be enhanced, whereas the second step would
not take place and fixation would be unstable in soluble phase.
Alternatively, such peptides might preferentially react with
HLA molecules after immobilization onto microplates.
Among the 40 peptides tested eight of eight described as
targets for human T cells (either CD8+ or CD4+), 5 of 8
described as targets for murine T cells and 11 of 24 of ran-
domly chosen HIV peptides evidenced positive binding to
HLA molecules. Using 36 peptides derived from HIV-1 nef,
preliminary results showed that the binding was also cor-
related to the recognition of peptide by human T cells. Our
results suggest a preferential association of human antigenic
peptides with HLA molecules and they also agree with the
well-known observation, that, in most cases, human and mu-
rine CTL do not recognize identical epitopes in a single viral
Table 8.
￿
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Results are expressed as concentration (uM) of competitor peptide giving 50% or inhibition in CTL lysis and IPBA. ND, Not done: this test
could not be performed since the competitor peptide was similar to the sensitizing one. N, No effect; E, enhancement.
Peptide
HLA-A2/M .Y+
CTL blocking
'am
57-68
IPBA
HLA-B37/N.335-349Y+
CTL blocking
#M
IPBA
M.Y+ 57-68 ND 0.1 3 3
Nef137-145 3 10 1 3
Vpr.68-80 10 1 30 10
Vif1-15 30 3 3 3
Vpr.55-68 30 3 50 10
N.335-349Y+ 50 0.3 ND' 10
Vif.60-72 50 30 100 100
Rev.18-30 100 100 100 100
Nef.113-128 >100 100 >100 >100
Env.312-327 >100 >100 N N
Nef.79-84 N N N N
N.47-158R - N N N N
Env.827-843 N N N N
A2.170-185 N N N N
XR.12-26 N N N N
Gag.265-279 E 30 or E E E
Lys.46-61 N 100 N 100protein. Moreover, it must be noted that among the murine
T cell target peptides, Env.312-327 which strongly bound HLA
molecules, was also described as a human T cell target (44).
In most cases, peptides identifiedas targets for human anti-
viral CTL reacted preferentially with their restriction HLA
molecule in the PBA. This preference was particularly ob-
vious when using certain low binders, but was not frequently
observed in the IPBA. The fact that antigenic peptides were
either strong or weak binders might be due to different align-
ments within the binding site ofHLA molecules as suggested
by others (45, 46). Altogether, our results indicated that ability
of a given peptide to bind HLA molecule was a prerequisite
for antigenicity but this binding ability alone could not ex-
plain the restriction phenomenon. As already suggested (7,
17, 18), the restriction must be determined at multiple levels,
and predominantly at the level of the T cell repertoire. Our
results are also in agreement with several reports describing
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